A special fluorescent in situ hybridization technique to study peripheral blood and assess the effectiveness of interferon therapy in chronic myeloid leukemia

Ismael Buño, William A. Wyatt, Alan R. Zinsmeister, Jeanne Dietz-Band, Richard T. Silver, Gordon W. Dewald

Research output: Contribution to journalArticle

62 Citations (Scopus)

Abstract

Using a highly sensitive fluorescence in situ hybridization method with probes for BCR and ABL1 (D-FISH), we studied 37 paired sets of bone marrow and blood specimens, collected within 24 to 96 hours of each other, from 10 patients before and during treatment for chronic myeloid leukemia (CML). The normal range for 500 interphase nuclei was ≤4 (≤0.8%) nuclei based on 10 bone marrow and 10 blood specimens from normal individuals. The percentage of neoplastic nuclei was usually lower in blood than bone marrow. However, changes in the percentage of neoplastic nuclei in blood and bone marrow tracked closely over the course of therapy and with the results of quantitative cytogenetic studies on bone marrow. This result indicates that D-FISH is useful to test blood from patients with CML to monitor therapy. Moreover, by analysis of 6,000 nuclei with D-FISH, residual disease was identified in bone marrow and blood for patients in complete cytogenetic remission. Consequently, D-FISH analyses of interphase nuclei from blood could substitute for Q-cytogenetic studies on bone marrow. Thus, it may not be necessary to collect bone marrow samples so frequently to monitor therapy in CML.

Original languageEnglish (US)
Pages (from-to)2315-2321
Number of pages7
JournalBlood
Volume92
Issue number7
StatePublished - Oct 1 1998
Externally publishedYes

Fingerprint

Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Fluorescence In Situ Hybridization
Interferons
Bone
Blood
Bone Marrow
Cytogenetics
Interphase
Therapeutics
Blood substitutes
Blood Substitutes
Hematologic Tests
Reference Values
Fluorescence

ASJC Scopus subject areas

  • Hematology

Cite this

Buño, I., Wyatt, W. A., Zinsmeister, A. R., Dietz-Band, J., Silver, R. T., & Dewald, G. W. (1998). A special fluorescent in situ hybridization technique to study peripheral blood and assess the effectiveness of interferon therapy in chronic myeloid leukemia. Blood, 92(7), 2315-2321.

A special fluorescent in situ hybridization technique to study peripheral blood and assess the effectiveness of interferon therapy in chronic myeloid leukemia. / Buño, Ismael; Wyatt, William A.; Zinsmeister, Alan R.; Dietz-Band, Jeanne; Silver, Richard T.; Dewald, Gordon W.

In: Blood, Vol. 92, No. 7, 01.10.1998, p. 2315-2321.

Research output: Contribution to journalArticle

Buño, I, Wyatt, WA, Zinsmeister, AR, Dietz-Band, J, Silver, RT & Dewald, GW 1998, 'A special fluorescent in situ hybridization technique to study peripheral blood and assess the effectiveness of interferon therapy in chronic myeloid leukemia', Blood, vol. 92, no. 7, pp. 2315-2321.
Buño, Ismael ; Wyatt, William A. ; Zinsmeister, Alan R. ; Dietz-Band, Jeanne ; Silver, Richard T. ; Dewald, Gordon W. / A special fluorescent in situ hybridization technique to study peripheral blood and assess the effectiveness of interferon therapy in chronic myeloid leukemia. In: Blood. 1998 ; Vol. 92, No. 7. pp. 2315-2321.
@article{4f48ddd62d3b4330bdba0c50b5f5f189,
title = "A special fluorescent in situ hybridization technique to study peripheral blood and assess the effectiveness of interferon therapy in chronic myeloid leukemia",
abstract = "Using a highly sensitive fluorescence in situ hybridization method with probes for BCR and ABL1 (D-FISH), we studied 37 paired sets of bone marrow and blood specimens, collected within 24 to 96 hours of each other, from 10 patients before and during treatment for chronic myeloid leukemia (CML). The normal range for 500 interphase nuclei was ≤4 (≤0.8{\%}) nuclei based on 10 bone marrow and 10 blood specimens from normal individuals. The percentage of neoplastic nuclei was usually lower in blood than bone marrow. However, changes in the percentage of neoplastic nuclei in blood and bone marrow tracked closely over the course of therapy and with the results of quantitative cytogenetic studies on bone marrow. This result indicates that D-FISH is useful to test blood from patients with CML to monitor therapy. Moreover, by analysis of 6,000 nuclei with D-FISH, residual disease was identified in bone marrow and blood for patients in complete cytogenetic remission. Consequently, D-FISH analyses of interphase nuclei from blood could substitute for Q-cytogenetic studies on bone marrow. Thus, it may not be necessary to collect bone marrow samples so frequently to monitor therapy in CML.",
author = "Ismael Bu{\~n}o and Wyatt, {William A.} and Zinsmeister, {Alan R.} and Jeanne Dietz-Band and Silver, {Richard T.} and Dewald, {Gordon W.}",
year = "1998",
month = "10",
day = "1",
language = "English (US)",
volume = "92",
pages = "2315--2321",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "7",

}

TY - JOUR

T1 - A special fluorescent in situ hybridization technique to study peripheral blood and assess the effectiveness of interferon therapy in chronic myeloid leukemia

AU - Buño, Ismael

AU - Wyatt, William A.

AU - Zinsmeister, Alan R.

AU - Dietz-Band, Jeanne

AU - Silver, Richard T.

AU - Dewald, Gordon W.

PY - 1998/10/1

Y1 - 1998/10/1

N2 - Using a highly sensitive fluorescence in situ hybridization method with probes for BCR and ABL1 (D-FISH), we studied 37 paired sets of bone marrow and blood specimens, collected within 24 to 96 hours of each other, from 10 patients before and during treatment for chronic myeloid leukemia (CML). The normal range for 500 interphase nuclei was ≤4 (≤0.8%) nuclei based on 10 bone marrow and 10 blood specimens from normal individuals. The percentage of neoplastic nuclei was usually lower in blood than bone marrow. However, changes in the percentage of neoplastic nuclei in blood and bone marrow tracked closely over the course of therapy and with the results of quantitative cytogenetic studies on bone marrow. This result indicates that D-FISH is useful to test blood from patients with CML to monitor therapy. Moreover, by analysis of 6,000 nuclei with D-FISH, residual disease was identified in bone marrow and blood for patients in complete cytogenetic remission. Consequently, D-FISH analyses of interphase nuclei from blood could substitute for Q-cytogenetic studies on bone marrow. Thus, it may not be necessary to collect bone marrow samples so frequently to monitor therapy in CML.

AB - Using a highly sensitive fluorescence in situ hybridization method with probes for BCR and ABL1 (D-FISH), we studied 37 paired sets of bone marrow and blood specimens, collected within 24 to 96 hours of each other, from 10 patients before and during treatment for chronic myeloid leukemia (CML). The normal range for 500 interphase nuclei was ≤4 (≤0.8%) nuclei based on 10 bone marrow and 10 blood specimens from normal individuals. The percentage of neoplastic nuclei was usually lower in blood than bone marrow. However, changes in the percentage of neoplastic nuclei in blood and bone marrow tracked closely over the course of therapy and with the results of quantitative cytogenetic studies on bone marrow. This result indicates that D-FISH is useful to test blood from patients with CML to monitor therapy. Moreover, by analysis of 6,000 nuclei with D-FISH, residual disease was identified in bone marrow and blood for patients in complete cytogenetic remission. Consequently, D-FISH analyses of interphase nuclei from blood could substitute for Q-cytogenetic studies on bone marrow. Thus, it may not be necessary to collect bone marrow samples so frequently to monitor therapy in CML.

UR - http://www.scopus.com/inward/record.url?scp=0032190169&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032190169&partnerID=8YFLogxK

M3 - Article

VL - 92

SP - 2315

EP - 2321

JO - Blood

JF - Blood

SN - 0006-4971

IS - 7

ER -